Although the differences in expression patterns of molecules such as MYC, BCL2, double expression of MYC and BCL2, p53, and CD5 between WR‐DLBCL subgroups and LN‐DLBCL subgroups were not significant, we showed that patients with LN‐DLBCL had significantly more stage II disease (76% vs. 69%) and bulky disease (7% vs. 1%) than those with WR‐DLBCL. Here, TP53 is linked to diffuse large B-cell lymphoma.